Contrast enhanced multi-detector CT (MD CT) is now the most commonly used imaging modality for detection of liver metastases and work-up of equivocal lesions found at ultrasound. MR imaging is an established technique for non-invasive characterisation of liver masses and for preoperative potentially resectable liver tumours. Diagnostic value of each modality strongly depends on the scan technique. With MDCT, the role of thin slice imaging has been well established, with slice thicknesses of 5--7.5 mm being inferior to thinner slices in terms of lesion detection \[[@B1]\]. The amount of contrast material as well as the flow rate influence enhancement of hypervascular lesions in the arterial phase and the magnitude of liver parenchyma enhancement in the venous phase, respectively \[[@B2],[@B3]\]. The number of CT scans varies with the local indication, with single-phasic venous scans to 4-phasic scans, as recommended by European and US guidelines for HCC detection and characterisation.

For MR imaging, a multi-point DIXON technique has replaced conventional T1-weighted GRE pulse sequences; with this technique in one breathhold in-phase, opposed-phase, fat-suppressed, and water-suppressed images can be obtained, without any spatial misregistration. Diffusion-weighted pulse sequences significantly improve detection of metastases \[[@B4],[@B5]\]. As a black-blood technique with T2-weighted image impression, it demonstrates small lesions without any blurring by an adjacent high signal intensity of vessels of bile ducts \[[@B6]\]. Administration of contrast agents is mandatory for liver MRI, with the choice of either non-specific gadolinium chelates or liver specific contrast agents. Indications for liver-specific contrast agents include preoperative evaluation of liver metastases and characterisation of hepatocellular lesions (FNH, adenoma), whereas non-specific gadolinium chelates are used for characterisation of haemangiomas, after liver resection or tumour ablation. The choice of the imaging techniques and the scan or contrast agent protocol should be tailored according to the clinical question.
